guia_fractura_cadera

Guía de buena práctica clínica en Geriatría. FRACTURA DE CADERA
24. Flicker L, MacInnis RJ, Dip Epi Biostat G, et al. Should older people in residential care receive
vitamine D to prevent falls? Results of a randomized trial. JAGS. 2005;53:1881-8.
25. Bischoff-Ferrari HA, Dawson-Hudghes B, Willett WC, et al. Effects of vitamine D on falls- a
meta-analysis. JAMA. 2004;291:1999-2006.
26. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, et al. Endogenous hormones
and the risk of hip and vertebral fractures among older women. Study of Osteoporotic
Fractures Research Group. N Engl J Med. 1998;339:733-8.
27. Hailey D, Sampietro-Colom L, Marshall D, Rico R, Granados A, Asua J. The effectiveness of
bone density measurement and associated treatments for prevention of fractures. An international
collaborative review. Int J Technol Assess Health Care. 1998;14:237-54.
28. Kenny AM. Tratamiento hormonal sustitutivo. En: GRS Geriatric Review Syllabus. 5.ª ed.
Barcelona: American Geriatric Society (Ed Esp). Barcelona: Medical Trends; 2003. p. 333-8.
29. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Mevitt MC, et al. Randomised
trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.
30. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al.
Effect of alendronate on risk of fracture in women with low bone density but without vertebral
fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.
31. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk
reduction with alendronato in women with osteoporosis: the fracture intervention trial. FIT
Research Group. J Clin Endocrinol Metab. 2000;85:4118-24.
32. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate
on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-40.
33. Boonen S, McClung MR, Eastell R, Fuleihan GE, Barton IP, Delmas P. Safety and efficacy of risedronate
in reducing fracture risk in osteoporotic women aged 80 and older: implications for
the use of antiresortive agents in the old and oldest old. J Am Geriatr Soc. 2004;52:1832-9.
34. Van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral
fractures. Br J Rheumatol. 1998;37:87-94.
35. Cranney A, Welch V, Adachi JD, et al. Etidronato for treating and preventing postmenopausal osteoporosis
(Cochrane review). En: Cochrane Llibrary, Issue 2. Chinchester: John Wiley & Sons; 2004.
36. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid
hormona (1-34) on fractures and bone mineral density in postmenopausal women with
osteoporosis. N Engl J Med. 2001;344:1434-41.
37. Register JY, Seaman E, De Vernejoul S, Adami J, Comspton C, Phenekos JP, et al. Strontium
ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis:
Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab.
2005;90:2816-22.
38. Gardner MJ, Brophy RH, Demetrakopoulos D, Koob J, Hong R, Rana A, et al. Interventions ti
improve osteoporosis treatment following hip fracture. A prospective randomized trial. J Bone
Joint Surg Am. 2005;87:3-7.
102